Journal: Microbiome

Article Title: Tumor-colonized Streptococcus mutans metabolically reprograms tumor microenvironment and promotes oral squamous cell carcinoma.

doi: 10.1186/s40168-024-01907-9

Figure Lengend Snippet: Fig. 5 Single-cell transcriptomic landscape reveals the shift of the cellular types during oral carcinogenesis, and KYNA is a predominant driving force for expansions and infiltrations of neutrophils in the TME of OSCC. A Overview of the workflow for scRNA-seq analyses of OLK and OSCC rat tongue tissues. B UMAP plot of the clustering results for 13 major cell types from OLK and OSCC tissues. C Stacked histogram of the percentages of different cells from OLK and OSCC tissues. D Quantitative analysis of neutrophils, macrophages, and T cells in non-epithelial cells in OLK and OSCC tissues. E H&E and IHC staining for CD11b in OLK and OSCC tissues of experimental rats. Scale bar: 600 µm for 4 × magnification and 300 µm for 10 × magnification. F Representative IHC staining images and statistical analysis of CD16 in saline and KYNA-treated 4NQO rats. Scale bars: 200 µm for 10 × magnification and 50 µm for 40 × magnification. G Representative flow cytometry dot plots and statistical analysis of CD11b + CD16 + neutrophils from the peripheral blood of OSCC patients after KYNA treatment. H Relative SLC7A8 expression in neutrophils from OSCC patients after KYNA treatment detected by RT-qPCR. I Representative flow cytometry dot plots and statistical analysis of AHR + neutrophils from OSCC patients after treatments with KYNA in indicated concentrations. In D, unpaired Student’s t-test; E and F, Mann– Whitney U test; G, H, and I, one-way ANOVA

Article Snippet: At week 20, the rats were sacrificed, and the tongues were dissected, and a longitudinal mid-lingual incision was made. (4) IL-1β/PD-L1monoclonal antibody (mAb) intervention (8 rats/group): (A) 4NQO + IL-1β mAb (200 μg/rat, BE0246, cloneB122, Bioxcell, USA); (B) 4NQO + KYNA + IL-1β mAb; (C) 4NQO + PD-L1 mAb (200 μg/rat, BE0383, clone 368A.4H1, Bioxcell, USA); (D) 4NQO + KYNA + PD-L1 mAb; (E) 4NQO + control IgG (200 μg/rat, BE0091, Bioxcell, USA).

Techniques: Immunohistochemistry, Saline, Flow Cytometry, Expressing, Quantitative RT-PCR, MANN-WHITNEY

Journal: Neurosurgical Review

Article Title: Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential

doi: 10.1007/s10143-025-04050-7

Figure Lengend Snippet: (A) Diffuse/fibrillary strong PD-L1 expression in glioblastoma (IHC, x400). (B) Diffuse/fibrillary PD-L1 moderate expression in glioblastoma (IHC, x200). (C) Diffuse/fibrillary and cytoplasmic weak PD-L1 expression in glioblastoma (IHC, x400). (D) High LC3B cytoplasmic expression in glioblastoma (IHC, x400). (E) Low LC3B expression in glioblastoma (IHC, x200)

Article Snippet: The sections placed in an endogenous peroxide block for 15 min and For purpose of antigen retrieval for both PDL-1 & LC3B, sections were treated in microwave of (600 W) by immersion of the slides in citrate puffer solution (PH 7) for 20 min subsequently applied PD-L1 (mouse monoclonal antibodies, CUSABIO, Houston, USA, clone no.14D8C2, product code: CSB-MA878942A1m, 1: 200 [ ]) and LC3B (mouse monoclonal antibody, CUSABIO, Houston, USA, Clone No. 18F2, Product Code CSB-MA171423, a dilution of 1: 100 for 60 min, and then immunocomplexes were visualized with diaminobenzidine for 10 min and covered by a coverslip.

Techniques: Expressing

Journal: Neurosurgical Review

Article Title: Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential

doi: 10.1007/s10143-025-04050-7

Figure Lengend Snippet: OS according to expression of each PD-L1& LC3B and PFS according to LC3B; ( A ) OS in patients with high PD-L1 expression= 8.07 ± 0.62(Mean±SE) with 95% C.I (6.85-9.281), moderate expression OS= 9.65 ± 1.00 with 95% C.I (7.68-11.62) and weak PD-L1 expression OS=23.14 ±1.26with 95%C.I (20.67-25.60). ( B ) OS in cases with high LC3B expression=9.88 ± 1.19 (Mean±SE) with 95%C.I (7.55-12.21), and in those with low expression =20.77 ± 1.42 with 95%C.I (17.99-23.56). ( C ) PFS in cases with High LC3B expression = 2.93 ± 0.33(Mean±S.E )with 95%C.I=2.27-3.58. PFS in cases with Low expression =8.47 ± 0.36 with 95%C.I =7.75-9.18

Article Snippet: The sections placed in an endogenous peroxide block for 15 min and For purpose of antigen retrieval for both PDL-1 & LC3B, sections were treated in microwave of (600 W) by immersion of the slides in citrate puffer solution (PH 7) for 20 min subsequently applied PD-L1 (mouse monoclonal antibodies, CUSABIO, Houston, USA, clone no.14D8C2, product code: CSB-MA878942A1m, 1: 200 [ ]) and LC3B (mouse monoclonal antibody, CUSABIO, Houston, USA, Clone No. 18F2, Product Code CSB-MA171423, a dilution of 1: 100 for 60 min, and then immunocomplexes were visualized with diaminobenzidine for 10 min and covered by a coverslip.

Techniques: Expressing